A detailed history of Atika Capital Management LLC transactions in Argenx Se stock. As of the latest transaction made, Atika Capital Management LLC holds 23,595 shares of ARGX stock, worth $14.7 Million. This represents 1.46% of its overall portfolio holdings.

Number of Shares
23,595
Previous 23,595 -0.0%
Holding current value
$14.7 Million
Previous $10.1 Million 26.12%
% of portfolio
1.46%
Previous 1.21%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$356.01 - $451.55 $1.1 Million - $1.4 Million
-3,100 Reduced 11.61%
23,595 $10.1 Million
Q4 2023

Feb 13, 2024

BUY
$338.91 - $506.01 $677,820 - $1.01 Million
2,000 Added 8.1%
26,695 $10.2 Million
Q1 2023

May 12, 2023

SELL
$334.23 - $403.65 $944,533 - $1.14 Million
-2,826 Reduced 10.27%
24,695 $9.2 Million
Q4 2022

Feb 13, 2023

SELL
$342.17 - $402.31 $2.9 Million - $3.41 Million
-8,479 Reduced 23.55%
27,521 $10.4 Million
Q3 2022

Nov 14, 2022

BUY
$343.2 - $395.75 $1.37 Million - $1.58 Million
4,000 Added 12.5%
36,000 $12.7 Million
Q2 2022

Aug 12, 2022

BUY
$269.58 - $378.88 $1.11 Million - $1.55 Million
4,100 Added 14.7%
32,000 $12.1 Million
Q1 2022

May 13, 2022

SELL
$254.45 - $351.06 $2.8 Million - $3.86 Million
-11,000 Reduced 28.28%
27,900 $8.8 Million
Q4 2021

Feb 11, 2022

SELL
$272.01 - $353.03 $598,422 - $776,665
-2,200 Reduced 5.35%
38,900 $13.6 Million
Q3 2021

Nov 12, 2021

BUY
$295.0 - $350.58 $295,000 - $350,580
1,000 Added 2.49%
41,100 $12.4 Million
Q2 2021

Aug 12, 2021

SELL
$257.11 - $319.92 $257,110 - $319,920
-1,000 Reduced 2.43%
40,100 $12.1 Million
Q1 2021

May 14, 2021

SELL
$268.3 - $380.31 $1.69 Million - $2.4 Million
-6,300 Reduced 13.29%
41,100 $11.3 Million
Q4 2020

Feb 16, 2021

BUY
$248.13 - $308.36 $645,138 - $801,736
2,600 Added 5.8%
47,400 $13.9 Million
Q3 2020

Nov 13, 2020

BUY
$215.51 - $272.51 $711,183 - $899,283
3,300 Added 7.95%
44,800 $11.8 Million
Q2 2020

Aug 13, 2020

SELL
$127.44 - $232.72 $955,800 - $1.75 Million
-7,500 Reduced 15.31%
41,500 $9.35 Million
Q1 2020

May 14, 2020

BUY
$108.83 - $165.23 $457,086 - $693,966
4,200 Added 9.38%
49,000 $6.46 Million
Q3 2019

Nov 14, 2019

BUY
$113.31 - $150.51 $328,599 - $436,479
2,900 Added 6.92%
44,800 $5.11 Million
Q2 2019

Aug 12, 2019

SELL
$115.0 - $141.58 $1.15 Million - $1.42 Million
-10,000 Reduced 19.27%
41,900 $5.93 Million
Q4 2018

Feb 14, 2019

SELL
$63.81 - $109.82 $748,491 - $1.29 Million
-11,730 Reduced 18.43%
51,900 $4.99 Million
Q3 2018

Nov 14, 2018

BUY
$75.5 - $96.63 $273,310 - $349,800
3,620 Added 6.03%
63,630 $4.83 Million
Q2 2018

Aug 14, 2018

BUY
$74.84 - $100.16 $1.72 Million - $2.3 Million
23,010 Added 62.19%
60,010 $4.97 Million
Q1 2018

May 15, 2018

BUY
$56.95 - $85.19 $2.11 Million - $3.15 Million
37,000 New
37,000 $2.98 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Atika Capital Management LLC Portfolio

Follow Atika Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atika Capital Management LLC with notifications on news.